KRAS and neoplasm: ShRNA-mediated NRP1 knockdown in KRAS wildtype cells increased cell viability and tumor growth by decreasing the SMAD2 phosphorylation, whereas a KRAS mutant reverses the increased viability and leads to tumor inhibition.